Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era

Best Practice and Research: Clinical Rheumatology

Volumn 25, Issue 3, 2011, Pages 375-388

  Nacci, Francesca ^a   Matucci Cerinic, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anti TNF ; Infections; Tuberculosis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; BCG VACCINE; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BRONCHITIS; COCCIDIOIDOMYCOSIS; ERYSIPELAS; GASTROENTERITIS; HEADACHE; HEPATITIS B; HEPATITIS C; HEPATITIS VIRUS; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; ILEUS; INFECTION; INFLUENZA; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MILIARY TUBERCULOSIS; MYCOSIS; NONHUMAN; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SINUSITIS; TUBERCULOSIS; TUBERCULOUS PERITONITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VARICELLA ZOSTER VIRUS; VEIN THROMBOSIS; VIRUS INFECTION;

EID: 81455139390     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2011.06.001     Document Type: Review

References (119)

1. M.G. Netea, T. Radstake, L.A. Joosten, J.W. van der Meer, P. Barrera, and B.J. Kullberg Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression Arthritis and Rheumatism 48 7 2003 Jul 1853 1857 (Pubitemid 36828680)
2. D. Schlüter, and M. Deckert The divergent role of tumor necrosis factor receptors in infectious diseases Microbes and Infection 2 10 2000 Aug 1285 1292
3. R.S. Wallis, M.S. Broder, J.Y. Wong, M.E. Hanson, and D.O. Beenhouwer Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clinical Infectious Diseases 38 9 2004 May 1 1261 1265 Epub 2004 Apr 15 (Pubitemid 38608568)
4. M.A. Gardam, E.C. Keystone, R. Menzies, S. Manners, E. Skamene, and R. Long Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infectious Diseases 3 3 2003 Mar 148 155 (Pubitemid 36278124)
5. C.D. Hamilton Infectious complications of treatment with biologic agents Current Opinion in Rheumatology 16 4 2004 Jul 393 398 (Pubitemid 38803140)
6. K.L. Hyrich, A.J. Silman, K.D. Watson, and D.P. Symmons Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety Annals of the Rheumatic Diseases 63 12 2004 Dec 1538 1543 (Pubitemid 39573679)
7. C. Popa, M.G. Netea, P. Barrera, T.R. Radstake, P.L. van Riel, and B.J. Kullberg Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy Cytokine 30 2 2005 Apr 21 72 77 (Pubitemid 40432632)
8. M.F. Doran, C.S. Crowson, G.R. Pond, W.M. O'Fallon, and S.E. Gabriel Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study Arthritis and Rheumatism 46 9 2002 Sep 2287 2293
9. H.A. Capell Disease modifying antirheumatic drugs: longterm safety issues Journal of Rheumatology Supplement 62 2001 10 15 (Pubitemid 32499917)
10. O.Y. Saliu, C. Sofer, D.S. Stein, S.K. Schwander, and R.S. Wallis Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity Journal of Infectious Diseases 194 4 2006 Aug 15 486 492 (Pubitemid 44162660)
11. W. Kievit, M.C. Creemers, J. Fransen, I.H. Kuper, M.A.F.J. Van der Laar, and T.L. Jansen A higher rate of serious infections in patients treated with TNF alpha blocking agents Arthritis and Rheumatism 54 Suppl. 9 2006 Abstract 825
12. Y. Komano, T. Nanki, M. Tanaka, R. Sakai, R. Koike, and N. Miyasaka Analysis of severe adverse events in patients with rheumatoid arthritis under the treatment with biologics; report from the registry of Japanese rheumatoid arthritis patients for long-term safety Annals of the Rheumatic Diseases 68 Suppl. 3 2009 435 Abstract FRI0237
13. M.J. Pérez-Sola, J. Torre-Cisneros, B. Pérez-Zafrilla, L. Carmona, M.A. Descalzo, J.J. Gómez-Reino BIOBADASER Study Group Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry Medicina Clinica (Barcelona) 2011 Apr 21
14. J. Askling, C.M. Fored, L. Brandt, E. Baecklund, L. Bertilsson, and L. Cöster Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden Arthritis and Rheumatism 52 7 2005 Jul 1986 1992 (Pubitemid 40994319)
15. J.P. Leombruno, T.R. Einarson, and E.C. Keystone The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Annals of Rheumatic Diseases 68 7 2009 Jul 1136 1145 Epub 2008 Aug 27
16. J. Listing, A. Strangfeld, S. Kary, R. Rau, U. von Hinueber, and M. Stoyanova-Scholz Infections in patients with rheumatoid arthritis treated with biologic agents Arthritis and Rheumatism 52 11 2005 Nov 3403 3412 (Pubitemid 41612206)
17. A. Alonso-Ruiz, J.I. Pijoan, E. Ansuategui, A. Urkaregi, M. Calabozo, and A. Quintana Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety BMC Musculoskeletal Disorders 9 2008 Apr 17 52
18. G. Gartlehner, R.A. Hansen, B.L. Jonas, P. Thieda, and K.N. Lohr The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis Journal of Rheumatology 33 12 2006 Dec 2398 2408 (Pubitemid 46067817)
19. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent New England Journal of Medicine 345 2001 1098 1104
20. F. Wolfe, K. Michaud, J. Anderson, and K. Urbansky Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy Arthritis and Rheumatism 50 2004 372 379 (Pubitemid 38198820)
21. N. Nakelchik, and J.E. Mangiano Reactivation of histoplasmosis after treatment with infliximab American Journal of Medicine 112 2002 78
22. T. Ellerin, R.H. Rubin, and M.E. Weinblatt Infections and anti-tumor necrosis factor alpha therapy Arthritis and Rheumatism 48 2003 3013 3022 (Pubitemid 37409310)
23. P.E. Lipsky, D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, and J.R. Kalden Infliximab and methotrexate in the treatment of rhematoid arthritis. Anti tumor necrosis factor trials in rheumatoid arthritis with concomitant therapy study group New England Journal of Medicine 343 2000 1594 1602
24. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Furst, and M.H. Weiseman Sustained improvement over two years in physical function, structural damage, and sign and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate Arthritis and Rheumatism 50 2004 1051 1065 (Pubitemid 38480815)
25. E.W. St Claire, D.M. van der Heijde, J.S. Smolen, R.N. Maini, J.M. Bathon, and P. Emery Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomization, controlled trial Arthritis and Rheumatism 50 2004 3432 3443 (Pubitemid 39488667)
26. A.K. Mohan, T.R. Coté, J.A. Block, A.M. Manadan, J.N. Siegel, and M.M. Braun Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor Clinical Infectious Diseases 39 2004 295 299 (Pubitemid 39050474)
27. M.C. Genovese, J.M. Bathon, R.W. Martin, R.M. Flaischmann, J.R. Tesser, and M.H. Schiff Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes Arthritis and Rheumatism 46 2002 1443 1450 (Pubitemid 34620189)
28. L. Klareskog, D. van der Hijde, J.P. de Jager, A. Gough, J. Kalden, and M. Malaise Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patient with rheumatoid arthritis: double-blind randomized controlled trial Lancet 363 2004 675 681 (Pubitemid 38296553)
29. P.L. van Riel, A.J. Taggart, J. Sany, M. Gaubitz, H.V. Nab, and R. Pedersen Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study Annals of Rheumatic Diseases 65 2006 1478 1483 (Pubitemid 44629126)
30. L. Klareskog, M. Gaubitz, V. Rodríguez-Valverde, M. Malaise, M. Dougados, and J. Wajdula Etanercept Stusy 301 Investigators. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis Clinical and Experimental Rheumatology 29 2 2011 Mar-Apr 238 247
31. D.E. Furst, M.H. Schiff, R.M. Fleischmann, V. Strand, C.A. Virbara, and D. Compagnone Adalimumab, a fully anti tumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30 2003 2563 2571 (Pubitemid 37549331)
32. L.B. van de Putte, C. Atkins, M. Malaise, J. Sany, A.S. Russel, and P.L.C.M. van Riel Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying anti rheumatic drug treatment has failed Annals of Rheumatic Diseases 63 2004 508 516 (Pubitemid 38530193)
33. M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, and C.A. Birbara Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis and Rheumatism 48 1 2003 Jan 35 45 (Pubitemid 36091645)
34. M.E. Weinblatt, E.C. Keystone, D.E. Furst, A.F. Kavanaugh, E.K. Chartash, and U.G. Segurado Long-term efficacy and safety of Adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study Annals of Rheumatic Diseases 65 2005 753 759
35. E.C. Keystone, A.F. Kavanaugh, J.T. Sharp, H. Tannenbaum, Y. Hua, and L.S. Teoh Radigraphic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled 52-week trial Arthritis and Rheumatism 50 2004 1400 1411 (Pubitemid 38608061)
36. M.H. Schiff, G.R. Burmester, J.D. Kent, A.L. Pangan, H. Kupper, and S.B. Fitzpatrick Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis Annals of Rheumatic Diseases 65 2006 889 894
37. V. Strand, P. Mease, G.R. Burmester, E. Nikaï, G. Coteur, and R. van Vollenhoven Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial Arthritis Research and Therapy 11 2009 R170
38. V. Strand, J.S. Smolen, R.F. van Vollenhoven, P. Mease, G.R. Burmester, and F. Hiepe Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial Annals of Rheumatic Diseases 70 6 2011 Jun 996 1002
39. J. Kay, E.L. Matteson, B. Dasgupta, P. Nash, P. Durez, and S. Hall Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study Arthritis and Rheumatism 58 2008 964 975 (Pubitemid 351563997)
40. P. Emery, R.M. Fleischmann, L.W. Moreland, E.C. Hsia, I. Strusberg, and P. Durez Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis Arthritis and Rheumatism 60 8 2009 Aug 2272 2283
41. J.S. Smolen, J. Kay, M.K. Doyle, R. Landewé, E.L. Matteson, J. Wollenhaupt GO-AFTER Study Investigators Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial Lancet 374 2009 210 221
42. J. Kremer, C. Ritchlin, A. Mendelsohn, D. Baker, L. Kim, and Z. Xu Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study Arthritis and Rheumatism 62 2010 917 928
43. J. Askling, C.M. Fored, L. Brandt, E. Baecklund, L. Bertilsson, and N. Feltelius Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists Annals of Rheumatic Diseases 66 10 2007 Oct 1339 1344 (Pubitemid 47492478)
44. W.G. Dixon, K. Watson, M. Lunt, K.L. Hyrich, A.J. Silman, D.P. Symmons British Society for Rheumatology Biologics Register Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register Arthritis and Rheumatism 54 8 2006 Aug 2368 2376 (Pubitemid 44204996)
45. F. Tubach, P. Ravaud, D. Salmon-Céron, N. Petitpain, O. Brocq, F. Grados Recherce Axée sur la Tolérance des Biothérapies Group Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists Clinical Infectious Diseases 43 10 2006 Nov 15 e95 100
46. J.J. Gómez-Reino, L. Carmona, V.R. Valverde, E.M. Mola, M.D. Montero BIOBADASER Group Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report Arthritis and Rheumatism 48 8 2003 Aug 2122 2127 (Pubitemid 36959191)
47. Safety update on TNF- a antagonists: infliximab and etanercept 17 August 2001 Food and Drug Administration Arthritis Drugs Advisory Commitee Available at: www.fda/gov/ohrms/dockats/ac/01/transcripts/3779+2-01.pdf
48. L. Ristić, M. Rancić, and M. Radović Tuberculosis in the 21st century-challenges, endeavours and recommendations to doctors Medicinski Pregled 63 11-12 2010 Nov-Dec 811 815
49. N.M. Parrish, J.D. Dick, and W.R. Bishai Mechanisms of latency in Mycobacterium tuberculosis Trends in Microbiology 6 3 1998 107 112 (Pubitemid 28123330)
50. World Health Organization, WHO Report 2008. Global tuberculosis control: surveillance, planning, financing, www.who.int/tb/pubblications/global-report/ 2008/pdf/fullreport.pdf.
51. E. Salgado, and J.J. Gómez-Reino The risk of tuberculosis in patients treated with TNF antagonists Expert Review of Clinical Immunology 7 3 2011 329 340
52. C.R. Horsburgh Jr. Priorities for the treatment of latent tuberculosis infection in the United States New England Journal of Medicine 350 20 2004 May 13 2060 2067
53. P.A. Jensen, L.A. Lambert, M.F. Iademarco, R. Ridzon Cdc Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005 Morbidity and Mortality Weekly Report Recommendations and Reports 54 RR-17 2005 Dec 30 1 141
54. D.E. Furst, R. Wallis, M. Broder, and D.O. Beenhouwer Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection Seminars in Arthritis and Rheumatism 36 3 2006 Dec 159 167 Epub 2006 Jul 3. Review (Pubitemid 44691882)
55. F. Tubac, D. Salmon, P. Ravaud, Y. Allanore, P. Goupille, M. Bréban Research Axed on Tolerance of Biotherapies Group Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry Arthritis and Rheumatism 60 7 2009 Jul 1884 1894
56. W.G. Dixon, K.L. Hyrich, K.D. Watson, M. Lunt, J. Galloway, A. Ustianowski B S R B R Control Centre Consortium, Symmons DP; BSR Biologics Register Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) Annals of Rheumatic Diseases 69 3 2010 Mar 522 528
57. S.S. Storage, H. Agrawal, and D.E. Furst Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis Korean Journal of Internal Medicine 25 1 2010 Mar 1 17
58. K.L. Winthrop, J.N. Siegel, J. Jereb, Z. Taylor, and M.F. Iademarco Tuberculosis associated with therapy against tumor necrosis factor alpha Arthritis and Rheumatism 52 10 2005 Oct 2968 2974 (Pubitemid 41447075)
59. A.M. Manadan, J.A. Block, and W. Sequeira Mycobacteria tuberculosis peritonitis associated with etanercept therapy Clinical and Experimental Rheumatology 21 4 2003 Jul-Aug 526 (Pubitemid 36950330)
60. L. Carmona, C. Hernández-García, C. Vadillo, E. Pato, A. Balsa, I. González-Alvaro EMECAR Study Group Increased risk of tuberculosis in patients with rheumatoid arthritis Journal of Rheumatology 30 7 2003 Jul 1436 1439 (Pubitemid 36835436)
61. L. Carmona, J.J. Gómez-Reino, V. Rodríguez-Valverde, D. Montero, E. Pascual-Gómez, E.M. Mola BIOBADASER Group Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis and Rheumatism 52 6 2005 Jun 1766 1772 (Pubitemid 40852885)
62. J.R. Curtis, N. Patkar, A. Xie, C. Martin, J.J. Allison, and M. Saag Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists Arthritis and Rheumatism 56 4 2007 Apr 1125 1133 (Pubitemid 46608637)
63. R.S. Wallis, M. Broder, J. Wong, A. Lee, and L. Hoq Reactivation of latent granulomatous infections by infliximab Clinical Infectious Diseases 41 Suppl. 3 2005 Aug 1 S194 S198 (Pubitemid 41022090)
64. C.D. Hamilton Tuberculosis in the cytokine era: what rheumatologists need to know Arthritis and Rheumatism 48 8 2003 Aug 2085 2091 (Pubitemid 36959186)
65. J. Keane TNF-blocking agents and tuberculosis: new drugs illuminate an old topic Rheumatology (Oxford) 44 2005 714 720 (Pubitemid 41487198)
66. X. Mariette, and D. Salmon French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers Annals of Rheumatic Diseases 62 8 2003 Aug 791 (Pubitemid 36886422)
67. D. Salmon Recommendations about the prevention and management of tuberculosis I patients taking infliximab Joint Bone Spine 69 2002 170 172 (Pubitemid 34450358)
68. http://agmed.sante.gouv.fr/htm/10/tnf/reco.pdf
69. J.E. Fonseca, H. Lucas, H. Canhão, R. Duarte, M.J. Santos, and M. Villar Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update Acta Reumatológica Portuguesa 33 2008 77 85
70. D.E. Furst, F.C. Breedveld, J.R. Kalden, J.S. Smolen, G.R. Burmester, and P. Emery Updated consensus statement on biological agents for the treatment of rheumatic diseases Annals of Rheumatic Diseases 65 Suppl. 3 2006 Nov iii2 iii15
71. J.J. Gómez-Reino, L. Carmona, M. Angel Descalzo Biobadaser Group Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection Arthritis and Rheumatism 57 5 2007 Jun 15 756 761 (Pubitemid 46932080)
72. British Thoracic Society Standards of Care Committee BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment Thorax 60 10 2005 Oct 800 805
73. R.E. Huebner, M.F. Schein, and J.B. Bass Jr. Tuberculine skin test Clinical Infectious Disease 17 1993 968 975
74. M. Pai, L.W. Riley, and J.M. Colford Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review Lancet Infectious Diseases 4 12 2004 Dec 761 776
75. D. Ponce de León, E. Acevedo-Vásquez, A. Sánchez-Torres, M. Cucho, J. Alfaro, and R. Perich Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis Annals of Rheumatic Diseases 64 9 2005 Sep 1360 1361 (Pubitemid 41206259)
76. W.S. Mow, M.T. Abreu-Martin, K.A. Papadakis, H.E. Pitchon, S.R. Targan, and E.A. Vasiliauskas High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy Clinical Gastroenterology and Hepatology 2 4 2004 Apr 309 313 (Pubitemid 38447195)
77. P.F. Barnes Diagnosing latent tuberculosis infection: the 100-year upgrade American Journal of Respiratory and Critical Care Medicine 163 2001 807 808 (Pubitemid 32275842)
78. G.H. Mazurek, J. Jereb, P. Lobue, M.F. Iademarco, B. Metchock, A. Vernon Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC) Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States Morbidity and Mortality Weekly Report Recommendations and Report 54 RR-15 2005 Dec 16 49 55
79. P. Andersen, M.E. Munk, J.M. Pollock, and T.M. Doherty Specific immune-based diagnosis of tuberculosis Lancet 356 9235 2000 Sep 23 1099 1104
80. T. Mori, M. Sakatani, F. Yamagishi, T. Takashima, Y. Kawabe, and K. Nagao Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens American Journal of Respiratory and Critical Care Medicine 170 1 2004 Jul 1 59 64 (Pubitemid 38997752)
81. Y.A. Kang, H.W. Lee, H.I. Yoon, B. Cho, S.K. Han, and Y.S. Shim Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country Journal of the American Medical Association 293 22 2005 Jun 8 2756 2761 (Pubitemid 40965087)
82. J. Sellam, H. Hamdi, C. Roy, G. Baron, M. Lemann, X. Puéchal RATIO (Research Axed on Tolerance of Biotherapies) Study Group Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy Annals of Rheumatic Diseases 66 12 2007 Dec 1610 1615 (Pubitemid 350205449)
83. F. Bartalesi, S. Vicidomini, D. Goletti, C. Fiorelli, G. Fiori, and D. Melchiorre QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases European Respiratory Journal 33 3 2009 Mar 586 593
84. D. Menzies, M. Pai, and G. Comstock Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research Annals of Internal Medicine 146 5 2007 Mar 6 340 354 (Pubitemid 351650594)
85. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control, www.nice.org.uk/CG33.
86. D.E. Furst, E.C. Keystone, J. Braun, F.C. Breedveld, G.R. Burmester, and F. De Benedetti Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 Annals of Rheumatic Diseases 70 Suppl. 1 2011 Mar i2 i36
87. American Thoracic Society and Centres for Disease Control and Prevention Targeted tuberculin testing and treatment of latent tuberculosis infection American Journal of Respiratory and Critical Care Medicine 161 2000 S221 S247
88. Centre for Disease Control Update: fatal and severe liver injurie associated with rifapin and pyrazinamide for latent tuberculosis infection, and revision in the American Thoracic Society/CDC recommendations-USA 2001 Morbidity and Mortality Weekly Report 50 2001 733 735
89. Centre for Disease Control Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia, 2000 Morbidity and Mortality Weekly Report 50 2001 289 291
90. J.L. Perez, H. Kupper, and G. Spencer-Green Impact of screening for latent TB prior to initiating anti TNF therapy in North America and Europe Quality and Safety in Health Care 64 2005 265
91. G. Murphy, D. Schmidt-Martin, B.G. Hynes, and S. Harney Systemic listeriosis with adalimumab therapy Journal of Clinical Rheumatology 15 7 2009 Oct 369 370
92. V.V. Jain, T. Evans, and M.W. Peterson Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area Respiratory Medicine 100 7 2006 Jul 1291 1293 (Pubitemid 43793058)
93. L. Bergstrom, D.E. Yocum, N.M. Ampel, I. Villanueva, J. Lisse, and O. Gluck Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists Arthritis and Rheumatism 50 6 2004 Jun 1959 1966 (Pubitemid 38725108)
94. E.G. Favalli, F. Desiati, F. Atzeni, P. Sarzi-Puttini, R. Caporali, and F.B. Pallavicini Marchesoni A.Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients Autoimmunity Reviews 8 3 2009 Jan 266 273
95. A. Strangfeld, and J. Listing Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy Best Practice and Research Clinical Rheumatology 20 6 2006 Dec 1181 1195 (Pubitemid 44774817)
96. C. Salliot, L. Gossec, A. Ruyssen-Witrand, M. Luc, M. Duclos, and S. Guignard Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients Rheumatology (Oxford) 46 2 2007 Feb 327 334 (Pubitemid 46189796)
97. J.D. Greenberg, G. Reed, J.M. Kremer, E. Tindall, A. Kavanaugh, C. Zheng CORRONA Investigators Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry Annals of Rheumatic Diseases 69 2 2010 Feb 380 386
98. A.L. Smitten, H.K. Choi, M.C. Hochberg, S. Suissa, T.A. Simon, and M.A. Testa The risk of hospitalized infection in patients with rheumatoid arthritis Journal of Rheumatology 35 3 2008 Mar 387 393 (Pubitemid 351374409)
99. L.H. Calabrese, N. Zein, and D. Vassilopoulos Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection Annals of Rheumatic Diseases 63 Suppl. 2 2004 Nov ii18 ii24
100. F. Wolfe, K. Michaud, and E.F. Chakravarty Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders Rheumatology (Oxford) 45 11 2006 Nov 1370 1375 (Pubitemid 44605471)
101. N. Balandraud, S. Guis, J.B. Meynard, I. Auger, J. Roudier, and C. Roudier Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis Arthritis and Rheumatism 57 5 2007 Jun 15 762 767 (Pubitemid 46932081)
102. C. Miceli-Richard, N. Gestermann, C. Amiel, J. Sellam, M. Ittah, and S. Pavy Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies Arthritis Research and Therapy 11 3 2009 R77
103. B. Kallinowski, K. Haseroth, G. Marinos, C. Hanck, W. Stremmel, and L. Theilmann Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection Clinical and Experimental Immunology 111 2 1998 Feb 269 277 (Pubitemid 28088306)
104. D.R. Nelson, H.L. Lim, C.G. Marousis, J.W. Fang, G.L. Davis, and L. Shen Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection Digestive Diseases and Sciences 42 12 1997 Dec 2487 2494 (Pubitemid 28103785)
105. F. Monsalve-De Castillo, T.A. Romero, J. Estévez, L.L. Costa, R. Atencio, and L. Porto Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases Clinical and Diagnostic Laboratory Immunology 9 6 2002 Nov 1372 1375 (Pubitemid 35283307)
106. D. Torre, C. Zeroli, M. Giola, G. Ferrario, G.P. Fiori, and G. Bonetta Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis Clinical Infectious Diseases 18 2 1994 Feb 194 198
107. J.W. Fang, W.W. Shen, A. Meager, and J.Y. Lau Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection American Journal of Gastroenterology 91 4 1996 Apr 748 753 (Pubitemid 26117956)
108. J.Y. Lau, N. Sheron, K.T. Nouri-Aria, G.J. Alexander, and R. Williams Increased tumor necrosis factor-alpha receptor number in chronic hepatitis B virus infection Hepatology 14 1 1991 Jul 44 50
109. J.R. Peterson, F.C. Hsu, P.A. Simkin, and M.H. Wener Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection Annals of Rheumatic Diseases 62 11 2003 Nov 1078 1082 (Pubitemid 37323572)
110. N.N. Zein Etanercept Study Group Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study Journal of Hepatology 42 3 2005 Mar 315 322 (Pubitemid 40254244)
111. I. Cavazzana, A. Ceribelli, R. Cattaneo, and F. Franceschini Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases Autoimmunity Reviews 8 2 2008 Dec 104 106
112. M.C. Garavaglia, and G. Altomare Etanercept therapy in patients with psoriasis and concomitant HCV infection International Journal of Immunopathology and Pharmacology 23 3 2010 Jul-Sep 965 969
113. C. Ferri, G. Ferraccioli, D. Ferrari, M. Galeazzi, G. Lapadula, C. Montecucco GISEA Group Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection Journal of Rheumatology 35 10 2008 Oct 1944 1949
114. O. Oniankitan, C. Duvoux, D. Challine, A. Mallat, X. Chevalier, and J.M. Pawlotsky Infliximab therapy for rheumatic diseases in patients with chronic rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports Clinical Rheumatology 27 8 2008 Aug 1069 1071
115. G. Millonig, M. Kern, O. Ludwiczek, K. Nachbaur, and W. Vogel Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World Journal of Gastroenterology 12 6 2006 Feb 14 974 976
116. M.B. Carroll, and M.A. Forgione Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action Clinical Rheumatology 29 9 2010 Sep 1021 1029
117. M. Michel, C. Duvoux, C. Hezode, and D. Cherqui Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease Journal of Rheumatology 30 7 2003 Jul 1624 1625 (Pubitemid 36835467)
118. L.H. Calabrese, N.N. Zein, and D. Vassilopoulos Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Annals of Rheumatic Diseases 65 8 2006 Aug 983 989 Epub 2006 Apr 20. Review (Pubitemid 44133258)
119. R. de Franchis, A. Hadengue, G. Lau, D. Lavanchy, A. Lok, and N. McIntyre EASL Jury. EASL International consensus conference on hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version) Journal of Hepatology 39 Suppl. 1 2003 S3 S25 (Pubitemid 37222643)